Last reviewed 2026-05-28 · How we verify

Chloralosane (CHLORALOSE)

Phase 2 active Small molecule ✓ Verified May 2026

Chloralosane (generic name: CHLORALOSE) is a chloralose drug. It is currently in Phase 2 development.

Chloralose works by inhibiting the enzyme glycogen phosphorylase, which plays a key role in glycogenolysis.

Chloralosane, also known as alpha-chloralose, is a small molecule. It has various synonyms, including ALFAMAT, alpha-chloralose, and alphakil.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CHLORALOSE
Drug class	chloralose
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of glycogen like a stored battery for your body's energy needs. Chloralose helps to block the release of energy from this stored battery, which can be useful in certain medical situations. However, this process can also have unintended effects on the body's energy balance and metabolism.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chloralosane CI brief — competitive landscape report
Chloralosane updates RSS · CI watch RSS

Frequently asked questions about Chloralosane

What is Chloralosane?

Chloralosane (CHLORALOSE) is a chloralose drug.

How does Chloralosane work?

Chloralose works by inhibiting the enzyme glycogen phosphorylase, which plays a key role in glycogenolysis.

What is the generic name of Chloralosane?

CHLORALOSE is the generic (nonproprietary) name of Chloralosane.

What drug class is Chloralosane in?

Chloralosane belongs to the chloralose class. See all chloralose drugs at /class/chloralose.

What development phase is Chloralosane in?

Chloralosane is in Phase 2.

Drug class: All chloralose drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing